Clinical trials: Epigenetics
Aging
The Effects Of Therapeutic Plasma Exchange (TPE) On Age Related Biomarkers And Epigenetics
The goal of this clinical trial is to assure the safety of long term therapeutic plasma exchange (TPE) with and without Intravenous Immunoglobulin (IVIG) and its effects on biomarkers and epigenetic biologic clocks in forty…
- Trial name
- NCT06534450
- Testing
- Therapeutic Plasma Exchange, IVIG
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Dobri Kiprov
Healthy
Effect of a Multivitamin/Multimineral/Phytochemical Dietary Supplement on Indices of Human Health
This is a global transcriptomics and epigenetic pilot study designed to identify changes in gene expression and DNA methylation patterns following the consumption of an MVM/phytochemical supplement in a small group of healthy…
- Trial name
- NCT03146312
- Testing
- MVM/phytochemical supplement
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- USANA Health Sciences
Vagina Disease, Diagnosis
Feasibility of the Oricol™ Sampling Device to Retrieve Vagina Mucus (Wall) Samples for Genomic & Epigenetic Analysis.
Primary Objective The primary objective is to explore the feasibility of collecting a vaginal sample using the OriCol™ Sampling Device. Secondary Objectives The study has secondary objectives to assess: 1.
- Trial name
- Ellele-01 (NCT05709119)
- Testing
- Quantification of human DNA retrieved and DNA fragmentation profile.
- Where
- United Kingdom
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Origin Sciences
Hepato Cellular Carcinoma (HCC)
Hepatocellular Carcinoma Identification Using Delta-HLD
HIDE (Hepatocellular Carcinoma Identification via Delta-HLD) is a proof-of-concept case-control study designed to evaluate the performance of delta-HLD, Epiliquid's proprietary liquid biopsy technology, in detecting…
- Trial name
- HIDE (NCT07148310)
- Where
- Argentina
- Volunteers
- 200 people
- Sponsor
- Epiliquid Holding, Inc
Open Angle Glaucoma (OAG), NAION( Non-arteritic Anterior Ischemic Optic Neuropathy)
Evaluating ER-100 for Safety in People With Glaucoma or Non-Arteritic Anterior Ischemic Optic Neuropathy (Optic Nerve Conditions)
The goal of this clinical trial is to evaluate the safety and tolerability of a single dose of ER-100 in adults with optic nerve conditions, specifically Open Angle Glaucoma (OAG) and Non-Arteritic Anterior Ischemic Optic…
- Trial name
- NCT07290244
- Testing
- ER-100 epigenetic therapy
- Where
- 4 sites in United States
- Volunteers
- 18 people
- Sponsor
- Life Biosciences Inc.
Colo-rectal Cancer
Colorectal Analysis for Signature Cancer Assessment Using Delta-HLD
CASCADE (Colorectal Analysis for Signature Cancer Assessment Using delta-HLD Technology) is a proof-of-concept case-control study designed to evaluate the performance of delta-HLD, Epiliquid's proprietary liquid biopsy…
- Trial name
- CASCADE (NCT07148297)
- Where
- Argentina
- Volunteers
- 600 people
- Sponsor
- Epiliquid Holding, Inc
Carcinoma, Non-Small-Cell Lung
Safety and Efficacy Study of CC-486 With MK-3475 to Treat Locally Advanced or Metastatic Non-small Cell Lung Cancer
The purpose of this study is to determine whether the combination therapy of CC-486 (oral azacitidine) and pembrolizumab provides improved patient outcomes compared to pembrolizumab alone in patients with previously treated…
- Trial name
- NCT02546986
- Testing
- CC-486, Pembrolizumab
- Where
- 33 sites in United States, France and 4 more
- Volunteers
- 100 people
- Sponsor
- Celgene
Solid Tumor
A Dose-Escalation Study of OBP-801 in Patients With Advanced Solid Tumors
This Phase 1a, single center, open-label, repeat dose study will evaluate the safety, efficacy, and Pharmacokinetics of ascending doses of OBP-801 in patients with advanced solid tumors.
- Trial name
- NCT02414516
- Testing
- OBP-801
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Oncolys BioPharma Inc
Advanced or Metastatic ER+ HER2- Breast Cancer (mBC), Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors
This is a first-in-human, open-label, multicenter phase 1 study to evaluate safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of OP-3136, a lysine acetyltransferases 6A and 6B (KAT6A/B)…
- Conditions
- Advanced or Metastatic ER+ HER2- Breast Cancer (mBC), Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC), Advanced or Metastatic Castration-Resistant Prostate Cancer (mCRPC), Metastatic Breast Cancer
- Trial name
- NCT06784193
- Testing
- OP-3136, Fulvestrant, Palazestrant
- Where
- 25 sites in United States, Australia and 4 more
- Volunteers
- 180 people
- Sponsor
- Olema Pharmaceuticals, Inc.
Breast Neoplasms
Study to Assess the Efficacy and Safety of the Epigenetic Modifying Effects of CC-486 (Oral Azacitidine) in Combination With Fulvestrant
The purpose of this study to Assess the Efficacy and Safety of the Epigenetic Modifying Effects of CC-486 (Oral Azacitidine) in Combination With Fulvestrant in Postmenopausal Women with estrogen receptor positive (ER+), human…
- Trial name
- NCT02374099
- Testing
- CC-486, Fulvestrant
- Where
- 35 sites in United States, Belgium and 4 more
- Volunteers
- 97 people
- Sponsor
- Celgene
Cancer
Development and Validation of Harbinger Health Test for Early Cancer Detection
This is a prospective, multi-center, observational study with a collection of biospecimens and clinical data from approximately 10,000 participants from up to 125 clinical network sites and locations in the United States.
- Trial name
- CORE-HH (NCT05435066)
- Testing
- Harbinger Health Test
- Where
- 128 sites in United States
- Volunteers
- 8,038 people, healthy volunteers welcome
- Sponsor
- Harbinger Health
Healthy
Natural Product System and Lifestyle Modification
The goal of this clinical trial is to learn whether four dietary supplements and lifestyle changes can affect gene expression and blood markers in healthy volunteers. The main questions it aims to answer are: 1.
- Trial name
- NCT06931977
- Testing
- Supplement system + copaiba softgels
- Where
- United States
- Volunteers
- 97 people, healthy volunteers welcome
- Sponsor
- dōTERRA International
Metastatic Breast Cancer
An Early Phase Study of Abraxane Combined With Phenelzine Sulfate in Patients With Metastatic or Advanced Breast Cancer
This phase 1b study will determine the safety and efficacy of combined treatment of Abraxane and phenelzine sulfate (Nardil) for metastatic or locally advanced breast cancer.
- Trial name
- Epi-PRIMED (NCT03505528)
- Testing
- Nanoparticle albumin-bound paclitaxel, Phenelzine Sulfate
- Where
- 3 sites in Australia
- Volunteers
- 8 people
- Sponsor
- EpiAxis Therapeutics
Acute Myelogenous Leukemia (AML)
A Randomized Study of Epigenetic Priming Using Decitabine With Front Line Induction Chemotherapy Compared With Immediate Induction Chemotherapy in Pediatric Acute Myelogenous Leukemia (AML) Subjects
The purpose of this study is to evaluate the efficacy and safety of decitabine when used before chemotherapy to treat leukemia in pediatric patients.
- Trial name
- NCT00943553
- Testing
- decitabine Induction Chemotherapy, Induction Chemotherapy
- Where
- India
- Sponsor
- Eisai Inc.
Epigenetics
Biomarker Study to Evaluate Correlations Between Epigenetic Aging and NAD+ Levels in Healthy Volunteers
This is a single center, prospective study to evaluate correlations between epigenetic aging (as measured via DNA methylation) and NAD+ levels in healthy volunteers.
- Trial name
- NCT04220658
- Testing
- Biomarker study
- Where
- United States
- Volunteers
- 170 people, healthy volunteers welcome
- Sponsor
- Elysium Health
Aging
AC-11 Supplement and Biological Aging
This is a prospective non-randomized clinical study of 24 patients to evaluate the effects of the AC-11®. The study will evaluate the effectiveness of the supplement's ability to reverse epigenetic markers of biological age.
- Trial name
- NCT05310123
- Testing
- AC-11
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- TruDiagnostic
Lung Cancer, Non-Small Cell
Novel Epigenetic Mapping in Cell-Free DNA for the Detection of Lung Cancer
This trial is a multicenter, open-label, non-interventional controlled study to identify and characterize epigenetic signatures of lung cancer.
- Trial name
- LumenDx (NCT06963307)
- Where
- Israel
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- JaxBio Ltd
Carcinoma, Non-Small-Cell Lung
Safety and Efficacy Study of Nab®-Paclitaxel With CC-486 or Nab®-Paclitaxel With Durvalumab, and Nab®-Paclitaxel Monotherapy as Second/Third-line Treatment for Advanced Non-small Cell Lung Cancer
This is a Phase 2, open-label, multicenter study to assess the efficacy and safety of second/third-line treatment with nab-paclitaxel in combination with the epigenetic modifying therapy of CC-486 or immunotherapy of durvalumab…
- Trial name
- abound2L+ (NCT02250326)
- Testing
- nab-paclitaxel IV, CC-486, Duravalumab
- Where
- 34 sites in United States, Canada and 5 more
- Volunteers
- 240 people
- Sponsor
- Celgene
AML, Adult, Myelodysplastic Syndromes
EPITHINK: Epigenetic Drug Treatment and Therapeutic Immunotherapy With NKR-2
This open-label Phase I study aims to define the recommended dose for further clinical development the NKR-2 treatment administered concurrently with AZA in treatment-naïve AML/MDS patients not candidates for intensive…
- Trial name
- EPITHINK (NCT03612739)
- Testing
- NKR-2 CAR-T Cells
- Sponsor
- Celyad Oncology SA
Aging
A Dosing Study of Hyperbaric Oxygen Therapy (HBOT) on Epigenetic Aging
This study aims to assess the impact of hyperbaric oxygen therapy on a number of outcomes, including epigenetic aging, inflammation, and cellular health.
- Trial name
- HBOT (NCT05297019)
- Testing
- Hyperbaric Oxygen Therapy
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- TruDiagnostic